Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Epistemonikos ID: f1f618b70c10de76a6df32df7af1997f713c160e
First added on: May 12, 2024